Forma Therapeutics Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forma Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Forma Therapeutics stock.
View analyst ratings for Forma Therapeutics or view top-rated stocks.

4 analysts have issued 12-month price targets for Forma Therapeutics' shares. Their FMTX stock forecasts range from $23.00 to $58.00. On average, they expect Forma Therapeutics' share price to reach $45.20 in the next year. This suggests a possible upside of 543.0% from the stock's current price.
View analysts' price targets for Forma Therapeutics or view top-rated stocks among Wall Street analysts.

Forma Therapeutics' stock was trading at $14.22 on January 1st, 2022. Since then, FMTX shares have decreased by 50.6% and is now trading at $7.03.
View the best growth stocks for 2022 here.

Forma Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Forma Therapeutics.

Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) posted its quarterly earnings data on Friday, May, 6th. The company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.11. During the same period in the previous year, the company earned ($0.76) EPS.
View Forma Therapeutics' earnings history.

Some companies that are related to Forma Therapeutics include Sana Biotechnology (SANA), SpringWorks Therapeutics (SWTX), Adaptive Biotechnologies (ADPT), Vericel (VCEL), REGENXBIO (RGNX), Vaxcyte (PCVX), Kymera Therapeutics (KYMR), Editas Medicine (EDIT), Replimune Group (REPL), Alector (ALEC), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), iTeos Therapeutics (ITOS), Atara Biotherapeutics (ATRA) and Instil Bio (TIL).
View all of FMTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Forma Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Trade Desk (TTD), Abbott Laboratories (ABT), CVS Health (CVS), Walt Disney (DIS), DocuSign (DOCU), Gilead Sciences (GILD), Intuit (INTU) and Neurocrine Biosciences (NBIX).

(FMTX) raised $201 million in an initial public offering on Friday, June 19th 2020. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. Jefferies' SVB Leerink and Credit Suisse acted as the underwriters for the IPO.

Forma Therapeutics trades on the NASDAQ under the ticker symbol "FMTX."

Forma Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.37%), State Street Corp (5.91%), Vanguard Group Inc. (4.77%), Deep Track Capital LP (3.50%), Renaissance Technologies LLC (1.35%) and Northern Trust Corp (0.66%). Company insiders that own Forma Therapeutics stock include Frank D Lee, Jeannette Potts, Patrick F Kelly and Todd Shegog.
View institutional ownership trends for Forma Therapeutics.

FMTX stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Citigroup Inc., Goldman Sachs Group Inc., Charles Schwab Investment Management Inc., BlackRock Inc., California State Teachers Retirement System, ProShare Advisors LLC, and Bank of America Corp DE. Company insiders that have sold Forma Therapeutics company stock in the last two years include Frank D Lee, Jeannette Potts, Patrick F Kelly, and Todd Shegog.
View insider buying and selling activity for Forma Therapeutics or view top insider-selling stocks.

FMTX stock was bought by a variety of institutional investors in the last quarter, including Deep Track Capital LP, State Street Corp, Renaissance Technologies LLC, Silverarc Capital Management LLC, Bollard Group LLC, PDT Partners LLC, Qube Research & Technologies Ltd, and Invesco Ltd..
View insider buying and selling activity for Forma Therapeutics or or view top insider-buying stocks.

Shares of FMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FMTX stock can currently be purchased for approximately $7.03.

Forma Therapeutics (NASDAQ:FMTX) has a market capitalization of $336.07 million and generates $100.56 million in revenue each year. The company earns $-172.96 million in net income (profit) each year or ($3.820010) on an earnings per share basis.

Forma Therapeutics employs 166 workers across the globe.

Forma Therapeutics' mailing address is 500 ARSENAL STREET SUITE 100, WATERTOWN MA, 02472. The official website for Forma Therapeutics is www.formatherapeutics.com. The company can be reached via phone at 617-679-1970 or via email at [email protected].